Osimertinib-Induced Cardiomyopathy

Osimertinib is the preferred treatment in patients with metastatic non–small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Shruti R., Brown, Sherry-Ann N., Kubusek, Jilan E., Mansfield, Aaron S., Duma, Narjust
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298525/
https://www.ncbi.nlm.nih.gov/pubmed/34317311
http://dx.doi.org/10.1016/j.jaccas.2019.12.038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298525/
https://www.ncbi.nlm.nih.gov/pubmed/34317311
http://dx.doi.org/10.1016/j.jaccas.2019.12.038

Ejemplares similares